会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • Novel sEH Inhibitors and Their Use
    • 新型sEH抑制剂及其用途
    • US20100249137A1
    • 2010-09-30
    • US12757089
    • 2010-04-09
    • Yun DINGReema K. ThaljiJoseph P. Marino, JR.
    • Yun DINGReema K. ThaljiJoseph P. Marino, JR.
    • A61K31/53C07D251/18A61P1/16A61P9/10A61P9/12A61P9/04A61P11/06A61P5/50A61P3/04A61P3/10
    • C07D241/46C07D251/18C07D251/52C07D401/04C07D401/12C07D401/14C07D403/12C07D409/04
    • The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to (Cis)-N-{[4-cyano-2-(trifluoromethyl)phenyl]methyl}-3-{[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt thereof, and N-{[4-cyano-2-(trifluoromethyl)phenyl]methyl}-3-{[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt thereof.The compounds of the invention can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension, asthma, and COPD. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    • 本发明涉及新型sEH抑制剂及其在治疗由sEH酶介导的疾病中的用途。 具体地,本发明涉及(C 1)-N - {[4-氰基-2-(三氟甲基)苯基]甲基} -3 - {[4-甲基-6-(甲基氨基)-1,3,5-三嗪 -2-基]氨基}环己烷甲酰胺; 或其药学上可接受的盐和N - {[4-氰基-2-(三氟甲基)苯基]甲基} -3 - {[4-甲基-6-(甲基氨基)-1,3,5-三嗪-2-基 - 吡啶-2-基]氨基}环己烷甲酰胺; 或其药学上可接受的盐。 本发明的化合物可用于治疗由sEH酶介导的疾病,如高血压,哮喘和COPD。 因此,本发明进一步涉及包含本发明化合物的药物组合物。 本发明还涉及使用本发明化合物或包含本发明化合物的药物组合物来抑制sEH和与之相关的病症的治疗方法。